As pressure mounts globally on drug pricing and development cost continues to rise, clinicians and translational scientists in biotech, academia and biopharma companies are re-evaluating when, where ...
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant efficacy in hematologic malignancies, but its broader clinical use is hindered by complex manufacturing, limited scalability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results